Topical delgocitinib, a pan-Janus kinase inhibitor, was well tolerated and reduced the severity and symptoms of disease in patients with moderate to severe chronic hand eczema, in two phase 3 trials.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A total of 40.3% of patients treated with dupilumab ...